Fibrogen Inc CS (FGEN)

$8.60 -0.10 (-1.15%)
Market Cap 35.20M
Revenue (ttm) 29.62M
Net Income (ttm) -47.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.63%
Debt to Equity Ratio 0.00
Volume 62,600
Avg Vol 31,978
Day's Range N/A - N/A
Shares Out 4.05M
Stochastic %K 10%
Beta 0.75
Analysts Sell
Price Target $43.00

Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 978 1200
Fax: 415 978 1902
Address:
350 Bay Street, Suite 10 #6009, San Francisco, United States
Iightning
Iightning Nov. 18 at 10:14 PM
1ightning® Options Trade Alert (Actionable) | Buy $FGEN Dec 19 $8 Call | Enter: $0.05 Exit: $0.07 | Profit: 45.06% ROI | https://1ightning.com
0 · Reply
MaxMiamiFl
MaxMiamiFl Nov. 18 at 3:25 PM
$FGEN The FibroGen CEO Thane Wettig bought shares within the last 7 days. From the latest Form 4 filings and insider-trade trackers: Nov 13, 2025: Bought 1,000 shares at $9.18 Nov 17, 2025: Bought 2,700 shares at about $9.10 Total over those two open-market purchases: 3,700 shares (~$33.7K).
0 · Reply
Iightning
Iightning Nov. 18 at 9:14 AM
1ightning® Options Trade Alert (Actionable) | Buy $FGEN Dec 19 $8 Call | Enter: $0.05 Exit: $0.07 | Profit: 45.06% ROI | https://1ightning.com
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Nov. 17 at 11:45 PM
$FGEN CEO purchased 3,700 shares at $9.12 for a total of $33,750. Wettig Thane now owns 24,979 shares. https://ceo-buys.com
0 · Reply
Mikesmillion
Mikesmillion Nov. 17 at 10:05 PM
$FGEN https://fibrogen.gcs-web.com/sec-filings/sec-filing/4/0001815638-25-000004 insider buying by mr ceo recently (11-13) not much but a beginning
1 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Nov. 17 at 6:56 AM
$FGEN leading Chemotherapy Induced Anemia Companies such as Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus, Cadila and others. mising Chemotherapy Induced Anemia Therapies such as Roxadustat and others https://www.openpr.com/news/4272266/chemotherapy-induced-anemia-treatment-market-size-in-the-7mm
1 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Nov. 17 at 6:54 AM
$FGEN Conclusion. In summary, Roxadustat effectively treats renal anemia by stimulating erythropoietin production and regulating iron metabolism. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1703424/full
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 16 at 11:07 AM
💎 LiquidTheta® Live Actionable Trade Asset: $FGEN Contracts: $FGEN January 15, 2027 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.83-$1.42 Profit Potential : 293% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Hanse2014
Hanse2014 Nov. 14 at 7:41 PM
$FGEN hope approval comes in
0 · Reply
Hanse2014
Hanse2014 Nov. 14 at 7:40 PM
$FGEN Why no insider buys on this Highlights ?
2 · Reply
Latest News on FGEN
FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 10:01 PM EST - 8 days ago

FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript

FibroGen to Report Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 15 days ago

FibroGen to Report Third Quarter 2025 Financial Results

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Sep 24, 2025, 7:00 AM EDT - 7 weeks ago

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 4:02 PM EDT - 2 months ago

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Aug 18, 2025, 7:00 AM EDT - 3 months ago

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 11:55 PM EDT - 3 months ago

FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:02 PM EDT - 3 months ago

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

FibroGen to Report Second Quarter 2025 Financial Results

Aug 4, 2025, 4:02 PM EDT - 3 months ago

FibroGen to Report Second Quarter 2025 Financial Results

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Jun 13, 2025, 8:22 AM EDT - 5 months ago

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

ADBE

FibroGen Announces 1-for-25 Reverse Stock Split

Jun 12, 2025, 4:02 PM EDT - 5 months ago

FibroGen Announces 1-for-25 Reverse Stock Split

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

Jun 9, 2025, 4:02 PM EDT - 5 months ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:31 PM EDT - 6 months ago

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:02 PM EDT - 6 months ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 8, 2025, 4:24 AM EDT - 6 months ago

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

FibroGen to Report First Quarter 2025 Financial Results

May 5, 2025, 4:05 PM EDT - 7 months ago

FibroGen to Report First Quarter 2025 Financial Results

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 4:05 PM EDT - 8 months ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 8:18 PM EDT - 8 months ago

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 17, 2025, 4:05 PM EDT - 8 months ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:45 PM EST - 9 months ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

Feb 20, 2025, 1:08 PM EST - 9 months ago

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

AZN

FibroGen sells China unit to AstraZeneca in deal worth $160 million

Feb 20, 2025, 6:40 AM EST - 9 months ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

AZN

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Feb 20, 2025, 6:30 AM EST - 9 months ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

FibroGen Appoints David DeLucia as Chief Financial Officer

Dec 16, 2024, 8:05 AM EST - 1 year ago

FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

Nov 12, 2024, 8:38 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

FibroGen Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

FibroGen Reports Third Quarter 2024 Financial Results

FibroGen to Report Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

FibroGen to Report Third Quarter 2024 Financial Results

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 11:32 AM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

Jul 31, 2024, 12:33 PM EDT - 1 year ago

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

FibroGen to Report Second Quarter 2024 Financial Results

Jul 30, 2024, 4:07 PM EDT - 1 year ago

FibroGen to Report Second Quarter 2024 Financial Results

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Jun 6, 2024, 12:38 PM EDT - 1 year ago

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:05 PM EDT - 1 year ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Jun 3, 2024, 4:02 PM EDT - 1 year ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 23, 2024, 5:05 PM EDT - 1 year ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

FibroGen to Participate in Upcoming Investor Conferences

May 7, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Participate in Upcoming Investor Conferences

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

May 6, 2024, 10:31 PM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

FibroGen Reports First Quarter 2024 Financial Results

May 6, 2024, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2024 Financial Results

FibroGen to Report First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Report First Quarter 2024 Financial Results

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 24, 2024, 4:02 PM EDT - 1 year ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Apr 2, 2024, 5:46 PM EDT - 1 year ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Mar 11, 2024, 7:00 AM EDT - 1 year ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 11:44 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

FibroGen regains rights to anemia drug from AstraZeneca

Feb 26, 2024, 4:18 PM EST - 1 year ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:06 PM EST - 1 year ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 26, 2024, 4:05 PM EST - 1 year ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 20, 2024, 7:00 AM EST - 1 year ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Feb 5, 2024, 7:00 AM EST - 1 year ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Jan 25, 2024, 7:00 AM EST - 1 year ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Dec 9, 2023, 5:02 PM EST - 2 years ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Iightning
Iightning Nov. 18 at 10:14 PM
1ightning® Options Trade Alert (Actionable) | Buy $FGEN Dec 19 $8 Call | Enter: $0.05 Exit: $0.07 | Profit: 45.06% ROI | https://1ightning.com
0 · Reply
MaxMiamiFl
MaxMiamiFl Nov. 18 at 3:25 PM
$FGEN The FibroGen CEO Thane Wettig bought shares within the last 7 days. From the latest Form 4 filings and insider-trade trackers: Nov 13, 2025: Bought 1,000 shares at $9.18 Nov 17, 2025: Bought 2,700 shares at about $9.10 Total over those two open-market purchases: 3,700 shares (~$33.7K).
0 · Reply
Iightning
Iightning Nov. 18 at 9:14 AM
1ightning® Options Trade Alert (Actionable) | Buy $FGEN Dec 19 $8 Call | Enter: $0.05 Exit: $0.07 | Profit: 45.06% ROI | https://1ightning.com
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Nov. 17 at 11:45 PM
$FGEN CEO purchased 3,700 shares at $9.12 for a total of $33,750. Wettig Thane now owns 24,979 shares. https://ceo-buys.com
0 · Reply
Mikesmillion
Mikesmillion Nov. 17 at 10:05 PM
$FGEN https://fibrogen.gcs-web.com/sec-filings/sec-filing/4/0001815638-25-000004 insider buying by mr ceo recently (11-13) not much but a beginning
1 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Nov. 17 at 6:56 AM
$FGEN leading Chemotherapy Induced Anemia Companies such as Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus, Cadila and others. mising Chemotherapy Induced Anemia Therapies such as Roxadustat and others https://www.openpr.com/news/4272266/chemotherapy-induced-anemia-treatment-market-size-in-the-7mm
1 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Nov. 17 at 6:54 AM
$FGEN Conclusion. In summary, Roxadustat effectively treats renal anemia by stimulating erythropoietin production and regulating iron metabolism. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1703424/full
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 16 at 11:07 AM
💎 LiquidTheta® Live Actionable Trade Asset: $FGEN Contracts: $FGEN January 15, 2027 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.83-$1.42 Profit Potential : 293% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Hanse2014
Hanse2014 Nov. 14 at 7:41 PM
$FGEN hope approval comes in
0 · Reply
Hanse2014
Hanse2014 Nov. 14 at 7:40 PM
$FGEN Why no insider buys on this Highlights ?
2 · Reply
Hanse2014
Hanse2014 Nov. 14 at 7:39 PM
$FGEN No financial investor take care.. bery sad
0 · Reply
MaxMiamiFl
MaxMiamiFl Nov. 13 at 11:30 PM
$FGEN https://finance.yahoo.com/news/live/stock-market-today-dow-tumbles-800-points-with-nasdaq-sp-500-hammered-as-investors-pare-rate-cut-bets-210136974.html
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Nov. 13 at 12:48 PM
$FGEN Roxadustat enhanced erythropoiesis and iron metabolism but showed no significant effect on kidney function. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1678846/pdf
1 · Reply
Red6213
Red6213 Nov. 12 at 9:53 PM
$FGEN Is it good time to enter? or do you guys think, it might go below $5 in a month?
0 · Reply
MaxMiamiFl
MaxMiamiFl Nov. 12 at 5:22 PM
$FGEN 14.19% wow!!!!!! plus yestersdays
1 · Reply
MaxMiamiFl
MaxMiamiFl Nov. 11 at 11:36 PM
$FGEN no insider buying.. nothing
2 · Reply
coolelel
coolelel Nov. 11 at 8:15 PM
$FGEN Looks like someone sold 72k shares
0 · Reply
MaxMiamiFl
MaxMiamiFl Nov. 11 at 5:14 PM
$FGEN
1 · Reply
BullRunner333
BullRunner333 Nov. 11 at 4:23 PM
$FGEN Went ou to $BYND . We are going for a short squeeze. You can join…
1 · Reply
MaxMiamiFl
MaxMiamiFl Nov. 11 at 3:31 PM
$FGEN I sold 500 shares at 11.25 Bough back at 10.78
1 · Reply
AceInTheHole18
AceInTheHole18 Nov. 11 at 2:21 PM
$FGEN trading below cash value, should be in the $20 range at a minimum
1 · Reply
d_risk
d_risk Nov. 10 at 11:40 PM
$FGEN - FIBROGEN INC - 10Q - Updated Risk Factors FGEN’s latest 10-Q flags new risks around clinical trial redesigns, patient enrollment, fierce competition, third-party reliance for manufacturing and partnerships, IP protection failures, stringent global data/privacy laws, regulatory hurdles, financing and litigation pressures, and challenges from recent workforce cuts and loan agreements. #Biotechnology #FinancingRisk #IPProtection #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/FGEN/10-Q/2025-11-10
1 · Reply